Position in SCLX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$43,075
-$100,943 QoQ
Shares Held
6,468
-45.2% QoQ
Ownership
0.076%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026UBS Group AG holds $15,459,475,363 across 21 Drug Manufacturers - General names. SCLX ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
4,043,568 | $3,719,152,536 | |
| 2 | ABBV |
AbbVie Inc.
|
14,051,196 | $3,055,994,614 | |
| 3 | JNJ |
Johnson & Johnson
|
10,209,327 | $2,495,567,886 | |
| 4 | MRK |
Merck & Co., Inc.
|
13,933,630 | $1,676,076,347 | |
| 5 | AZN |
Astrazeneca PLC
|
5,981,411 | $1,179,653,872 | |
| 6 | AMGN |
Amgen Inc
|
3,148,040 | $1,107,637,870 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
3,930,216 | $547,754,202 | |
| 8 | PFE |
Pfizer Inc
|
17,609,150 | $494,464,929 |
All Filings in SCLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $43,075 | 6,468 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $144,018 | 11,805 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $504,788 | 25,650 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $108,527 | 18,426 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||